Xencor (NASDAQ:XNCR – Get Free Report)‘s stock had its “outperform” rating reiterated by equities researchers at Wedbush in a research note issued on Thursday, RTT News reports. They presently have a $34.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $36.00. Wedbush’s price objective points to a potential upside […]
Wedbush reiterated their outperform rating on shares of Nuvalent (NASDAQ:NUVL – Free Report) in a research note released on Friday morning, Benzinga reports. Wedbush currently has a $99.00 price objective on the stock. Other analysts have also issued reports about the stock. Jefferies Financial Group started coverage on shares of Nuvalent in a research note […]
Elevation Oncology, Inc. (NASDAQ:ELEV – Get Free Report) has been given a consensus recommendation of “Buy” by the six research firms that are covering the stock, Marketbeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokerages that have covered the stock in the last year […]
Nuvalent, Inc. (NASDAQ:NUVL – Get Free Report) Director Matthew Shair sold 37,500 shares of Nuvalent stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $65.84, for a total transaction of $2,469,000.00. Following the completion of the sale, the director now directly owns 1,424,698 shares of […]
HC Wainwright reiterated their buy rating on shares of TG Therapeutics (NASDAQ:TGTX – Free Report) in a research note published on Thursday, Benzinga reports. HC Wainwright currently has a $45.00 price target on the biopharmaceutical company’s stock. TGTX has been the subject of a number of other reports. The Goldman Sachs Group boosted their price […]